A securities class action lawsuit, Broadwater v. Ardelyx, Inc., et al. (Case No. 1:26-cv-14270), has been filed in the United States District Court for the District of Massachusetts on behalf of investors who acquired Ardelyx securities between Jan. 13, 2025, and Aug. 6, 2026, inclusive. Gainey McKenna & Egleston said the complaint alleges that Ardelyx and its executives made misleading statements or concealed commercial-performance and growth challenges affecting XPHOZAH and IBSRELA, including payer access and reimbursement barriers, stricter prior authorization and step-edit requirements, slower new-patient starts and delayed prescription fulfillment. On Aug. 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH revenue guidance, citing increased payer utilization-management processes and evolving market dynamics. The stock fell from $4.87 on Aug. 6 to $4.00 on Aug. 7, a decline of about 18%. Investors have until Nov. 16, 2026, to seek appointment as lead plaintiff. Faruqi & Faruqi also previously announced an investigation into potential claims and invited investors to discuss their rights.